StockNews.AI
ALXO
StockNews.AI
98 days

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

1. ALX Oncology will host a webcast on May 20, 2025, regarding ALX2004. 2. ALX2004 has received FDA Investigational New Drug clearance earlier this year. 3. The drug targets EGFR-expressing tumors, aiming for improved patient outcomes. 4. Company executives will detail clinical progress in the upcoming event. 5. Evorpacept, ALXO's lead candidate, is under various ongoing clinical trials.

4m saved
Insight
Article

FAQ

Why Bullish?

The FDA clearance and forthcoming webcast signal strong future development for ALX2004, boosting investor confidence, similar to past biotech successes that rallied on positive regulatory news.

How important is it?

The article discusses critical updates on ALX2004 and ALX Oncology's strategic direction, directly influencing price action and investor sentiment.

Why Short Term?

The webcast and new updates could generate immediate investor interest leading to short-term price movements, as witnessed with similar biotech events prior to clinical trial updates.

Related Companies

VRTXRGENREGN
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year. ALX2004 was fully designed and developed in-house by ALX Oncology scientists. By leveraging the Company’s proprietary, highly differentiated topoisomerase I inhibitor payload platform, ALX2004 optimizes ADC-based mechanisms of anti-tumor activity and is designed to improve outcomes in patients with EGFR-expressing tumors. ALX Oncology leadership Jason Lettmann, Chief Executive Officer, Alan Sandler, Chief Medical Officer and Marija Vrljic, Vice President of Antibody Technologies, will discuss planned clinical progress and updates for ALX2004 during the virtual webcast event. ALX2004 Webcast InformationThe virtual event will be webcast live and a replay will be available after the event by visiting the "Investors" section of ALX Oncology’s website and selecting "Events and Presentations."  Date & Time: Tuesday, May 20, 2025, 8:00 a.m. PT/11:00 a.m. ETWebcast Access: https://edge.media-server.com/mmc/p/ohnn53h5 About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Investor Relations Contact:Elhan Webb, CFA, IR Consultantewebb@alxoncology.com Media Contact:Audra Friis, Sam Brown Healthcare Communicationsaudrafriis@sambrown.com(917) 519-9577

Related News